The content on this site is intended for healthcare professionals only
Dr Gil Morgan from OncoAlert gives his oncology highlights from social media for the week of July 26 - August 1, 2021.
Alerts this week cover papers from New England, Nature Cancer and Lancet Oncology.
Dr Morgan also highlights the FDA approval of pembrolizumab for high-risk early stage triple negative breast cancer.
You can watch Dr Morgan's previous roundup here.
Follow Dr Morgan on twitter: @OncoAlert
Follow ecancer on twitter: @ecancer
ASCO 2026: Breast cancer overview
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Guiding transplant decisions in multiple myeloma with MRD
Revolutionising multiple myeloma treatment with CAR T-Cell therapies
Isa-KRd quad regimen in NDMM: MIDAS and CONCEPT studies
Patient reported outcomes for telisotuzumab vedotin in c-Met protein overexpressing EGFR WT nonsquamous NSCLC
Endocrine therapy plus trastuzumab and pertuzumab shows excellent survival outcomes in HR and HER2 positive early BC
Glofit-GemOx shows clinically meaningful benefit in relapsed/refractory diffuse large B-cell lymphoma
TP53 mutations are linked to unfavourable prognosis in chronic lymphocytic leukaemia
